Evaluating the Impact of Data Standardization on Real‐World Data
Pharmacoepidemiology and Drug Safety · 2025-08 · 34 (8)
DOI: 10.1002/pds.70191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 05.08.2025. Verfasst von Elizabeth M Garry und 8 weiteren Autor:innen. Beteiligte Einrichtung: Aetion, Inc., New York, New York, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
Purpose
To understand the impact of standardizing administrative healthcare data to the Sentinel common data model for cohort selection and descriptive findings.
Methods
Among patients with an outpatient COVID‐19 diagnosis (January 2021–December 2022) in HealthVerity using the data in its native and the standardized format, we descriptively compared cohort attrition and sample size, patient characteristics, and healthcare resource utilization during baseline and incidence of selected conditions after COVID‐19 diagnosis.
Results
The standardized cohort included fewer patients than the native (164 445 vs. 198 317), but age (median 48 years) and sex (70% female) were the same. The distribution of race was similar; however, the standardized cohort mapped patients with “Other” race to the “Unknown/Missing” race category, which created differences among those categories. Distributions were similar, albeit slightly lower for comorbidities (differences < 1%), and lower for SARS‐CoV‐2 diagnostic tests (59% vs. 70%). Medical encounter counts were also lower, with substantial differences that were attenuated after limiting encounter counts to one event per day (e.g., mean count of 6.0 vs. 27.7 specialty care visits reduced to 2.9 vs. 3.5). Incidence rates were lower, with the greatest difference for hepatotoxicity (29.6 vs. 37.1 per 1000 person‐years).
Conclusions
The data standardization refines the data (e.g., removes duplicate claims and variables or variable categories), which may reduce outliers and errors but yield lower distributions and counts of certain variables than observed in native format data. Therefore, it is critical to understand how standardization impacts the data and subsequently its fitness for use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aetion, Inc., New York, New York, USA.
- Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Office of the Commissioner, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Elizabeth M Garry, Wei Liu, Marie C Bradley
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Garry, E. M., Baglivo, A., Govil, P., Duryea, J. L., Liu, W., Lasky, T., Chakravarty, A., Rivera, D. R., & Bradley, M. C. (2025). Evaluating the Impact of Data Standardization on Real‐World Data. Pharmacoepidemiology and Drug Safety, 34(8). https://doi.org/10.1002/pds.70191
Vancouver
Garry EM, Baglivo A, Govil P, Duryea JL, Liu W, Lasky T, et al. Evaluating the Impact of Data Standardization on Real‐World Data. Pharmacoepidemiology and Drug Safety. 2025;34(8). doi:10.1002/pds.70191
BibTeX
@article{Garry2025,
author = {Garry, Elizabeth M and Baglivo, Aidan and Govil, Priya and Duryea, Jennifer L and Liu, Wei and Lasky, Tamar and Chakravarty, Aloka and Rivera, Donna R and Bradley, Marie C},
title = {Evaluating the Impact of Data Standardization on Real‐World Data},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
volume = {34},
number = {8},
doi = {10.1002/pds.70191}
}
EUVIMED